About Caladrius

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease.

News

March 5, 2020
Caladrius Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

February 27, 2020
Caladrius Biosciences to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Thursday, March 5, 2020 at 4:30 p.m. Eastern Time

February 3, 2020
Caladrius Biosciences to Participate at Upcoming February Conferences

Events

March 5, 2020
Caladrius Biosciences 4th Quarter and Full Year 2019 Financial Results and Business Update Conference Call

February 18, 2020
Noble Capital Markets’ 16th Annual Investor Conference

November 6, 2019
Caladrius Biosciences 3rd Quarter 2019 Financial Results and Business Update Conference Call

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

T Regulatory Cell Technology

CD34 Cell Technology